Clinical Trials Directory

Trials / Completed

CompletedNCT00673881

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Radiant Research · Academic / Other
Sex
All
Age
21 Years – 75 Years
Healthy volunteers
Accepted

Summary

The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglyceride \[TG\] concentrations). 2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL. 3. To obtain pilot data for power calculations for subsequent comparative study.

Detailed description

This trial assesses the effects of ABT-335 on RCT as measured by cholesterol efflux or rate of appearance of cholesterol (Ra in mg/kg/hr), cholesterol excretion (%/day), RCT efflux (mg/kg/day) and de novo cholesterol synthesis (%) during a baseline period (7 days) and during a treatment period (94 days). The goal of using RCT to reverse atherosclerosis is to increase the rate of cholesterol export or "efflux" from the tissues and plaques. An increase in this cholesterol efflux rate should shrink arterial plaques by decreasing their static accumulation of cholesterol. While some currently marketed drugs have a positive impact on RCT by increasing the rate of cholesterol excretion from the body, no drug has yet been approved to increase the rate of cholesterol efflux from the tissues

Conditions

Interventions

TypeNameDescription
DRUGcholine fenofibrate135 mg choline fenofibrate daily(oral, capsule)

Timeline

Start date
2008-03-01
Primary completion
2009-05-01
Completion
2009-05-01
First posted
2008-05-07
Last updated
2011-04-20
Results posted
2011-04-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00673881. Inclusion in this directory is not an endorsement.